News Curated �鶹��ý Channel: National Institute of Allergy and Infectious Diseases (NIAID)

NIH Grant Awarded to Study HIV Drug-Resistant Genetic Mutations Across Africa

Institute of Human Virology at the University of Maryland School of Medicine — Thu, 14 Apr 2022 09:00:20 EST

University of Maryland School of Medicine (UMSOM)'s Institute of Human Virology (IHV) researchers received funding from the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) for $2.7 million to study genetic changes in two genes from the HIV-1 virus that may make it resistant to antiretroviral therapy.

NIAID Director Anthony Fauci to Speak at Uniformed Services University Packard Lecture

Uniformed Services University of the Health Sciences (USU) — Thu, 07 Apr 2022 10:05:15 EST

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) and White House Chief Medical Advisor, will present "COVID-19: Progress and Priorities in the 3rd Year of a Historic Pandemic" when he delivers the 2022 David Packard Award Lecture at the Uniformed Services University of the Health Sciences (USU), Monday, April 11, 2022.

Promising antibody cocktail takes on Ebola virus--and its deadly cousin

La Jolla Institute for Immunology — Thu, 17 Mar 2022 12:05:00 EST

The team's latest study, published in Cell, shows that two clever human antibodies can target two ebolavirus species at once: Ebola virus and Sudan virus. These two species are responsible for the biggest, deadliest outbreaks. The new report suggests researchers could combine these two potent antibodies to make a powerful antiviral therapy.

Study Shows mRNA Vaccine Technology Can Be Used For HIV Vaccines

Duke Health — Tue, 15 Mar 2022 11:05:27 EST

Using mRNA technology like that in the COVID-19 vaccines, researchers have demonstrated a successful way to deliver a potential HIV vaccine, researchers at Duke Human Vaccine Institute report.

Trial of innovative HIV vaccine using mRNA technology enrolls first participant

HIV Vaccine Trials Network — Mon, 14 Mar 2022 09:00:04 EST

The first 12 study participants have been enrolled in a new Phase 1 clinical trial using the messenger ribonucleic acid (mRNA) vaccine technology developed by Moderna. The study evaluates the safety of and immune responses to three different experimental vaccines against HIV. This randomized, open-label trial represents one of the first clinical studies of the use of mRNA vaccine technology against HIV.

COVID Infection Rates in Hillsborough County May Have Been Higher Than Reported at Height of Pandemic

Moffitt Cancer Center — Mon, 14 Mar 2022 08:05:33 EST

In a new article published in the March issue of Emerging Infectious Diseases, Moffitt researchers set out to estimate the percentage of Hillsborough County residents who had COVID infection and better understand demographics and behavioral factors associated with infection.

Mutations Leading to Omicron Variant Did Not Enable Virus to Fully Escape Immune System

Johns Hopkins Medicine — Fri, 11 Mar 2022 09:25:45 EST

People who gained immunity -- either through vaccination or exposure -- against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen's omicron variant, says an international research team from Johns Hopkins Medicine.

Microneedle approach to address peanut allergy shows promise in mice

Michigan Medicine - University of Michigan — Fri, 04 Mar 2022 10:05:02 EST

Mice that received treatments with peanut-coated microneedles had significant increased rates of desensitization to peanut allergy compared with epicutaneous immunotherapy (EPIT), a new study found. The microneedle treatment success was achieved despite applying a dose of peanut protein 10-times lower than the dose delivered by EPIT. Researchers say the findings demonstrate the potential for peanut microneedles to improve food allergen immunotherapy through the skin.

New structure studies of a critical Nipah virus component may lead to vaccine, antibody treatments

Uniformed Services University of the Health Sciences (USU) — Fri, 04 Mar 2022 08:05:30 EST

Researchers at the Uniformed Services University in collaboration with University of Washington, have recently uncovered new details about how Nipah and Hendra viruses infect cells and the immune responses that can block them, which could ultimately lead to the development of new tactics to prevent and treat these deadly illnesses.

Are MAIT Cells Key to the Next Wave of Immunotherapy and Vaccine Development?

Stony Brook University — Thu, 24 Feb 2022 11:15:27 EST

A Stony Brook University physician-scientist has identified that mucosal-associated invariant T (MAIT) cells exercise several complex roles during healthy and disease states. The published findings may help to serve as a benchmark for future research on MAIT cells as targets for immunotherapies and vaccines.

UCLA-led team launches new center to study Valley Fever

University of California, Los Angeles (UCLA), Health Sciences — Thu, 10 Feb 2022 07:00:11 EST

A team led by UCLA researchers will receive a multi-million dollar grant to study why some people suffer from a devastating fungal infection called Valley Fever, while others suffer seemingly no impact from the disease.

Shorter Treatment is Better for Young Children with Outpatient Pneumonia

Vanderbilt University Medical Center — Fri, 04 Feb 2022 11:20:56 EST

Five days of antibiotics is superior to 10 days for children with community-acquired pneumonia who are not hospitalized, according to a study published in JAMA Pediatrics.

Cancer researcher awarded $2.3 million for research toward improving CAR T-cell therapy

Children's Hospital Los Angeles — Thu, 03 Feb 2022 08:05:09 EST

In preliminary studies, CHLA researchers have found that increasing the activity of a specific gene inside T-cells makes the T-cells stronger and longer-lasting. This line of research could lead to broader applications for CAR T-cell therapy in treating other cancers that have not responded to this therapy in the past. Chintan Parekh, MD, a physician scientist in the Cancer and Blood Disease Institute at Children's Hospital Los Angeles, has received a five-year, $2.3 million grant from the National Institute of Allergy and Infectious Diseases to pursue this line of research further.

Duke Institute Lands Federal Contract to Make Vaccine Candidates

Duke Health — Tue, 14 Dec 2021 10:35:15 EST

The National Institute of Allergy and Infectious Diseases awarded researchers at the Duke Human Vaccine Institute a contract that enables it to compete for projects advancing investigational vaccines to production for use in early clinical trials.

Reducing lung transplant rejection aim of clinical trial funded with $22 million grant

Washington University in St. Louis — Thu, 18 Nov 2021 17:20:50 EST

Physicians at Washington University School of Medicine in St. Louis and Massachusetts General Hospital/Harvard Medical School in Boston have received a seven-year, $22 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to help lead a multicenter clinical trial evaluating whether a novel immunosuppressant can reduce the risk of organ rejection after a lung transplant.

Unraveling the pseudoknot: Research to explore the 'switch' behind COVID virus

Binghamton University, State University of New York — Tue, 16 Nov 2021 09:00:32 EST

Binghamton University Chemistry Professor Eriks Rozners has received a two-year $428,330 grant from the National Institute of Allergy and Infectious Diseases for a research project which explores the "switch" behind the coronavirus.

Unexpected Antibody Type Found in People with Malaria Infections

University of Maryland School of Medicine — Tue, 02 Nov 2021 15:55:22 EST

In a newly published study, researchers at the University of Maryland School of Medicine have detected antibodies primarily made in response to infections in the mucous membranes -- in such areas as the lungs, intestines, or vagina -- in study participants with malaria.

Duke, UNC-Chapel Hill Scientists Identify New Antibody For COVID-19 and Variants

Duke Health — Tue, 02 Nov 2021 10:00:23 EST

A research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the original SARS illness.

In Covid-19 Vaccinated People, Those with Prior Infection Likely to Have More Antibodies

Johns Hopkins Medicine — Mon, 01 Nov 2021 14:00:04 EST

In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable -- that is, remain higher over an extended period of time -- in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.

COVID vaccine booster increases antibody responses, is protective in rhesus macaques

NIH, National Institute of Allergy and Infectious Diseases (NIAID) — Fri, 22 Oct 2021 16:25:39 EST

A booster dose of the mRNA-1273 COVID-19 vaccine given to rhesus macaques about six months after their primary vaccine series significantly increased levels of neutralizing antibodies against all known SARS-CoV-2 variants of concern, according to a new study from National Institutes of Health scientists and colleagues.